Genetic/Genomic Test for CNS/ Neuromusc Dis: 83.3% of denials overturned
In 12 California IMR decisions from 2019 to 2024, reviewers overturned 10 (83.3%). In the last five years: 66.7% of 6. 2 were medical-necessity disputes, 10 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 2 | 50.0% |
| 2023 | 3 | 100.0% |
| 2024 | 1 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 3 | 100.0% | 83.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Athena ataxia panel testing. The requested service is a diagnostic test and not a treatment. In this case, there is nothing in the patient’s clinical presentation or family history to suggest a specific cause of ataxia that would warrant a specific test …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for genetic testing. Neurodegenerative disease accounts for the majority of dementia diagnoses. These range from common dementia diagnoses such as Alzheimer's disease to frontotemporal dementia (FTD) and prion diseases. Genetic testing has helped identify several etiologies of dementia. The standard available testing is genetic panel testing. Whole exome …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for the Invitae Comprehensive Muscular Dystrophy Panel [33-Genes].Neuromuscular disorders consist of a genetically and phenotypically heterogeneous group of diseases disrupting any component of the neuraxis of the peripheral nervous system. These disrupted components can be skeletal muscle, neuromuscular junction, or nerves. The causes can be genetic (single gene …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for genetic testing, Select MDx. MDx testing and MDx with magnetic resonance imaging (MRI) are currently being evaluated to reduce the number of unnecessary biopsies in patients to support a decision for active surveillance. In the clinical scenario of a significant increase in prostate-specific antigen …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Genetic/Genomic Test denials for CNS/ Neuromusc Dis overturned?
In 12 California IMR decisions from 2019 to 2024, reviewers overturned 10 (83.3%). In the last five years: 66.7% of 6. 2 were medical-necessity disputes, 10 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.